University of Cape Town

uct.ac.za

Total trials

115

Active

16

Phase 3

15

Total enrollment

155,962

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Prednisone2
Levofloxacin2
Rifampin1
Rifampicin, Pyrazinamide, Ethambutol and Isoniazid1
Atorvastatin 40mg1
High dose rifampicin2

Next readouts

  • 2025-09-15
  • 2025-09-30
  • 2025-12-15

Top conditions

  • Tuberculosis20
  • HIV9
  • HIV Infections6
  • Malaria5
  • Hiv4
  • Obesity3
  • Child Behaviour Problems2
  • COVID-192

Frequently asked questions about University of Cape Town

How many clinical trials does University of Cape Town have on ClinicalTrials.gov?
University of Cape Town is listed as the lead sponsor on 115 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Cape Town's trials are in Phase 3?
15 of University of Cape Town's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does University of Cape Town focus on?
University of Cape Town's most-studied conditions on ClinicalTrials.gov are Tuberculosis, HIV, HIV Infections, Malaria, Hiv.
When are University of Cape Town's next clinical trial readouts?
University of Cape Town has 3 upcoming primary-completion readouts tracked here; the soonest is “High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis”, expected around 2025-09-15.